PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions

ASLAN Pharmaceuticals Limited (ASLN)

Equity · Currency in USD · Last updated Dec 2, 2023
SummaryFinancials

Company Info

ISINUS04522R1014
CUSIP04522R101
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$11.97M
EPS-$2.96
Revenue (TTM)$12.00M
Gross Profit (TTM)$79.82M
EBITDA (TTM)-$44.13M
Year Range$0.63 - $4.69
Target Price$16.00
Short %0.30%
Short Ratio2.36

Share Price Chart


Loading data...

Performance

The chart shows the growth of an initial investment of $10,000 in ASLAN Pharmaceuticals Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%JulyAugustSeptemberOctoberNovemberDecember
-97.75%
72.51%
ASLN (ASLAN Pharmaceuticals Limited)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ASLN

ASLAN Pharmaceuticals Limited

Return

ASLAN Pharmaceuticals Limited had a return of -65.00% year-to-date (YTD) and -77.39% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-65.00%19.67%
1 month-41.67%8.42%
6 months-85.00%7.29%
1 year-77.39%12.71%
5 years (annualized)-52.33%10.75%
10 years (annualized)N/A9.87%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2023-3.61%-8.75%-35.34%-9.96%-11.53%-40.43%-38.39%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for ASLAN Pharmaceuticals Limited (ASLN) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ASLN
ASLAN Pharmaceuticals Limited
-0.86
^GSPC
S&P 500
0.91

Sharpe Ratio

The current ASLAN Pharmaceuticals Limited Sharpe ratio is -0.86. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00JulyAugustSeptemberOctoberNovemberDecember
-0.86
0.91
ASLN (ASLAN Pharmaceuticals Limited)
Benchmark (^GSPC)

Dividend History


ASLAN Pharmaceuticals Limited doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-98.77%
-4.21%
ASLN (ASLAN Pharmaceuticals Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ASLAN Pharmaceuticals Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ASLAN Pharmaceuticals Limited was 98.77%, occurring on Dec 1, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.77%Jun 8, 20181381Dec 1, 2023
-10.31%May 31, 20181May 31, 20182Jun 4, 20183
-7.38%May 14, 201810May 25, 20181May 29, 201811
-2.32%May 7, 20181May 7, 20181May 8, 20182
-0.4%Jun 6, 20181Jun 6, 20181Jun 7, 20182

Volatility Chart

The current ASLAN Pharmaceuticals Limited volatility is 24.21%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%JulyAugustSeptemberOctoberNovemberDecember
24.21%
2.79%
ASLN (ASLAN Pharmaceuticals Limited)
Benchmark (^GSPC)